trazodone has been researched along with Smith-Lemli-Opitz Syndrome in 1 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
Smith-Lemli-Opitz Syndrome: An autosomal recessive disorder of CHOLESTEROL metabolism. It is caused by a deficiency of 7-dehydrocholesterol reductase, the enzyme that converts 7-dehydrocholesterol to cholesterol, leading to an abnormally low plasma cholesterol. This syndrome is characterized by multiple CONGENITAL ABNORMALITIES, growth deficiency, and INTELLECTUAL DISABILITY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Korade, Z | 1 |
| Genaro-Mattos, TC | 1 |
| Tallman, KA | 1 |
| Liu, W | 1 |
| Garbett, KA | 1 |
| Koczok, K | 1 |
| Balogh, I | 1 |
| Mirnics, K | 1 |
| Porter, NA | 1 |
1 other study available for trazodone and Smith-Lemli-Opitz Syndrome
| Article | Year |
|---|---|
Vulnerability of
Topics: Adult; Aripiprazole; Cholesterol; Enzyme Inhibitors; Female; Fibroblasts; Humans; Male; Middle Aged; | 2017 |